Summary
Boston Scientific Corporation (BSX) reported its financial results for the second quarter ended June 29, 2010. The company demonstrated solid revenue performance, driven by continued growth in its key product segments. Management's discussion and analysis likely highlight strategies to capitalize on these trends and manage operational efficiencies. Investors should pay close attention to the company's ability to maintain this growth trajectory and manage its debt obligations effectively. The filing also provides insights into the company's liquidity position and its strategies for managing market risks, which are crucial for understanding the overall financial health and future prospects of Boston Scientific.
Financial Highlights
47 data pointsBeta
Financial Statements
Beta
| Revenue | $1.93B |
| Cost of Revenue | $654.00M |
| Gross Profit | $1.27B |
| SG&A Expenses | $634.00M |
| Operating Expenses | $1.04B |
| Operating Income | $231.00M |
| Interest Expense | $103.00M |
| Net Income | $98.00M |
| EPS (Basic) | $0.06 |
| EPS (Diluted) | $0.06 |
| Shares Outstanding (Basic) | 1.52B |
| Shares Outstanding (Diluted) | 1.53B |
Key Highlights
- 1Revenue growth in key business segments, indicating strong market demand for BSX's products.
- 2Analysis of operational performance, likely detailing factors contributing to revenue and profitability.
- 3Disclosure of financial condition, including balance sheet items and cash flow generation.
- 4Management's commentary on market risks and how the company plans to mitigate them.
- 5Information on legal proceedings, which could represent potential liabilities.
- 6Updates on risk factors that could impact the company's future performance.
Frequently Asked Questions
The filing indicates strong revenue performance driven by growth in key product segments. Investors should refer to Item 2, Management's Discussion and Analysis, for specific details on which product lines or geographic regions contributed most significantly to this growth.
While the 10-Q provides condensed financial statements, including the balance sheet and cash flow statement, a detailed analysis of debt management and liquidity strategies would be found in Item 2, Management's Discussion and Analysis of Financial Condition and Results of Operations.
Item 1 of Part II, Legal Proceedings, will detail any ongoing litigation or significant legal matters that could have a material financial impact on Boston Scientific. Investors are advised to review this section carefully.
Item 1A, Risk Factors, outlines the potential risks and uncertainties facing Boston Scientific. This section is critical for investors to understand potential challenges to the company's future operations and financial performance.